Camoteskimab is under clinical development by Apollo Therapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Camoteskimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Camoteskimab overview

Camoteskimab (AEVI-007) is under development for the treatment of atopic dermatitis.

It was also under development for adult onset Still’s disease (Rheumatoid arthritis). It is administered intravenously as water for injection. It is a fully humanized monoclonal antibody acts by targeting interleukin 18. It was under development for the treatment chronic obstructive pulmonary disease (COPD) and  relapsed or refractory multiple myeloma.

Apollo Therapeutics overview

Apollo Therapeutics is a biopharmaceutical company, advancing transformative therapeutic programs based biological hypotheses in the therapeutic areas of oncology, inflammatory disorders, and rare diseases. Apollo Therapeutics is headquartered in Cambridge, England, the UK.

For a complete picture of Camoteskimab’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.